Legend Biotech Corporation American Depositary Shares (LEGN) Stock Price

LEGNStock

$18.48−42.89%52W

Market Cap$3.59B

P/E—

PEG Ratio—

Div yield—

Beta0.57

LEGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.03%

Price vs S&P 500 (4W)1.06%

VGM Score65.67

Book Value / Share (Quarterly)$2.71

P/TBV (Annual)5.75x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)106.41%

Cash Flow / Share (Quarterly)$-0.35

Price vs S&P 500 (YTD)-26.92%

Gross Margin (TTM)56.58%

Net Profit Margin (TTM)-7.20%

EPS (TTM)$-0.25

10-Day Avg Trading Volume2.14M

EPS Excl Extra (TTM)$-0.25

Revenue Growth (5Y)68.83%

EPS (Annual)$-0.81

ROI (Annual)-20.96%

Gross Margin (Annual)60.34%

Net Profit Margin (5Y Avg)-241.38%

Cash / Share (Quarterly)$2.56

Revenue Growth QoQ (YoY)51.93%

ROA (Last FY)-17.12%

Revenue Growth TTM (YoY)59.56%

EBITD / Share (TTM)$-0.03

ROE (5Y Avg)-40.14%

Operating Margin (TTM)-4.34%

Cash Flow / Share (Annual)$-0.35

P/B Ratio3.12x

P/B Ratio (Quarterly)4.54x

Net Income / Employee (Annual)$-102,300

EV / Revenue (TTM)2.71x

Net Interest Coverage (TTM)-0.88x

ROA (TTM)-5.39%

EPS Incl Extra (Annual)$-0.81

Current Ratio (Annual)1.96x

Quick Ratio (Quarterly)2.89x

3-Month Avg Trading Volume2.37M

52-Week Price Return-42.89%

Revenue / Employee (TTM)$438,400

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)3.73x

Asset Turnover (Annual)0.59x

52-Week High$37.50

Operating Margin (5Y Avg)-242.40%

EPS Excl Extra (Annual)$-0.81

CapEx CAGR (5Y)-10.50%

Tangible BV CAGR (5Y)127.48%

26-Week Price Return-1.12%

Quick Ratio (Annual)1.89x

13-Week Price Return-16.98%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)3.04x

Enterprise Value$3.44B

Revenue / Share Growth (5Y)54.47%

Asset Turnover (TTM)0.75x

Book Value / Share Growth (5Y)116.84%

Revenue / Employee (Annual)$354,800

Inventory Turnover (Annual)14.60x

Pretax Margin (Annual)-27.47%

Cash / Share (Annual)$2.56

3-Month Return Std Dev58.60%

Net Income / Employee (TTM)$-31,600

ROE (Last FY)-29.62%

Net Interest Coverage (Annual)-1.22x

EPS Basic Excl Extra (Annual)$-0.81

Receivables Turnover (TTM)92.19x

Total Debt / Equity (Quarterly)0.23x

EPS Incl Extra (TTM)$-0.25

Receivables Turnover (Annual)106.14x

ROI (TTM)-6.43%

P/S Ratio (TTM)3.02x

Pretax Margin (5Y Avg)-241.58%

Revenue / Share (Annual)$2.79

Tangible BV / Share (Annual)$2.83

Forward P/E41.22x

Price vs S&P 500 (52W)-58.42%

Year-to-Date Return-15.00%

5-Day Price Return3.82%

EPS Normalized (Annual)$-0.81

ROA (5Y Avg)-25.07%

Net Profit Margin (Annual)-28.85%

Month-to-Date Return-7.09%

EBITD / Share (Annual)$-0.29

Operating Margin (Annual)-13.27%

LT Debt / Equity (Annual)0.29x

ROI (5Y Avg)-31.05%

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$-0.25

P/TBV (Quarterly)6.34x

P/B Ratio (Annual)3.97x

Inventory Turnover (TTM)14.32x

Pretax Margin (TTM)-4.43%

Book Value / Share (Annual)$2.71

Price vs S&P 500 (13W)-19.67%

Beta0.57x

P/FCF (Annual)13.38x

Revenue / Share (TTM)$3.28

ROE (TTM)-8.70%

52-Week Low$16.24

vGradeC

gGradeA

mGradeC

vgmGradeB

LEGN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	$0.28	$0.32	+14.29%(+$0.04)
Q4 2025	Mar 10, 2026	$0.19	-$0.16	-184.42%(-$0.35)
Q3 2025	Nov 12, 2025	-$0.18	-$0.22	-18.92%(-$0.04)
Q2 2025	Aug 11, 2025	-$0.23	-$0.68	-195.65%(-$0.45)

LEGN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.17

4.18

4.09

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LEGNLegend Biotech Corporation American Depositary Shares	C	A	C	3.0x	59.6%	56.6%	—	$18.48
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Legend Biotech Corporation American Depositary Shares

Legend Biotech is a biopharmaceutical company developing cell therapies for cancer treatment. Its lead program, LCAR-B38M/JNJ-4528, is a CAR-T therapy in development for multiple myeloma. The company generates revenue through licensing and collaboration agreements, primarily with US partners.

LEGN Next Earnings Report

Report dateNov 11, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.01

Revenue estimate$359.91M

Also reporting on Nov 11, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

LEGN Insider Transactions

SellSep 29, 2026
SANDERS CORAZON CORSEE D
Director
Shares: 27,370Value: $515,103
SellSep 21, 2026
SANTOS CARLOS E
Chief Financial Officer
Shares: 5,430Value: $100,618

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

DFTXDefinium Therapeutics, Inc. Common SharesPharmaceutical Preparations
CBTCabot CorporationIndustrial Chemicals
ADPTAdaptive Biotechnologies Corporation Common StockBiological Products
IPARInterparfums, Inc. Common StockCosmetics & Toiletries
AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products
SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$16.24

High$37.50